SELLAS Life Sciences (SLS) Current Leases (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Current Leases of $562000.0 for Q1 2026, little changed year-over-year from $561000.0 in Q1 2025, and up 3.31% quarter-over-quarter from $544000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Current Leases (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Current Leases for 13 consecutive years, with $562000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases changed 0.18% year-over-year to $562000.0; the TTM figure through Mar 2026 stood at $562000.0 (changed 0.18% YoY), while the FY2025 annual figure was $544000.0, changed 0.0% from the prior year.
- Current Leases climbed to $562000.0 in Q1 2026 per SLS's latest filing, from $544000.0 in the prior quarter.
- Across five years, Current Leases topped out at $599000.0 in Q3 2025 and bottomed at $325000.0 in Q1 2022.
- Historically, Current Leases has averaged $480294.1 across 5 years, with a median of $488000.0 in 2024.
- Annual changes were most pronounced in 2022 — Current Leases soared 87.88% — and 2025, when it changed 0.0%.
- SELLAS Life Sciences' Current Leases stood at $372000.0 in 2022, then climbed by 19.89% to $446000.0 in 2023, then gained by 21.97% to $544000.0 in 2024, then changed by 0.0% to $544000.0 in 2025, then increased by 3.31% to $562000.0 in 2026.
- Business Quant data shows SLS's Current Leases at $562000.0 in Q1 2026, $544000.0 in Q4 2025, and $599000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 580,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 580,000.00 |
| Mar 31, 2026 | 562,000.00 |
| Dec 31, 2025 | 544,000.00 |
| Sep 30, 2025 | 599,000.00 |
| Jun 30, 2025 | 580,000.00 |
| Mar 31, 2025 | 561,000.00 |
| Dec 31, 2024 | 544,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Jun 30, 2024 | 531,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Dec 31, 2023 | 446,000.00 |
| Sep 30, 2023 | 466,000.00 |
| Jun 30, 2023 | 447,000.00 |
| Mar 31, 2023 | 427,000.00 |
| Dec 31, 2022 | 372,000.00 |
| Sep 30, 2022 | 356,000.00 |
| Jun 30, 2022 | 341,000.00 |
| Mar 31, 2022 | 325,000.00 |
| Dec 31, 2021 | 198,000.00 |
| Sep 30, 2021 | 190,000.00 |